For the quarter ending 2026-03-31, CHE had -$57,659K decrease in cash & cash equivalents over the period. $71,103K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 66,302 | 76,751 | 64,237 | 124,250 |
| Depreciation and amortization | 16,873 | 16,330 | 16,234 | 32,277 |
| Stock option expense | 9,249 | 8,297 | 6,067 | 18,307 |
| Benefit for deferred income taxes | -4,737 | 10,315 | -3,016 | -13,243 |
| Noncash long-term incentive compensation | 1,386 | 1,829 | -216 | 3,273 |
| Litigation settlements | - | -425 | 1,850 | - |
| Noncash directors' compensation | - | 0 | 0 | 1,123 |
| Amortization of debt issuance costs | 80 | 80 | 81 | 160 |
| Increase in accounts receivable | 32,899 | -32,807 | 30,937 | 13,466 |
| Decrease in inventories | -335 | -695 | -910 | 955 |
| Increase in prepaid expenses | 88 | -7,759 | 1,371 | 7,232 |
| Increase/(decrease) in accounts payable and other current liabilities | 2,235 | -15,296 | 22,551 | -12,449 |
| Change in current income taxes | 26,817 | -4,055 | 8,602 | -10,764 |
| Net change in lease assets and liabilities | 471 | 230 | 504 | 72 |
| (increase)/decrease in other assets | 3,603 | 5,213 | 6,378 | -48,426 |
| Increase in other liabilities | 6,709 | 4,069 | 4,834 | 1,521 |
| Other sources | 31 | -180 | 445 | 194 |
| Net cash provided by operating activities | 88,219 | 133,533 | 83,389 | 171,350 |
| Business combinations, net of cash acquired | 20,610 | 0 | 0 | 225 |
| Capital expenditures | 17,116 | 16,348 | 17,359 | 29,088 |
| Proceeds from sale of fixed assets | 134 | 817 | 3,271 | 480 |
| Other uses | 197 | 420 | 146 | 322 |
| Net cash used by investing activities | -37,789 | -15,951 | -14,234 | -29,155 |
| Purchases of treasury stock | 190,039 | 174,556 | 180,776 | 76,168 |
| Proceeds from revolving line of credit | 135,480 | - | - | - |
| Payments on revolving line of credit | 44,280 | - | - | - |
| Dividends paid | 8,173 | 8,499 | 8,654 | 14,542 |
| Capital stock surrendered to pay taxes on stock-based compensation | 1,482 | 335 | 0 | 8,484 |
| Proceeds from exercise of stock options | 1,312 | 0 | 0 | 27,152 |
| Change in cash overdrafts payable | -493 | 10,360 | 301 | 309 |
| Other (uses)/sources | -414 | 211 | -178 | 1,092 |
| Net cash used by financing activities | -108,089 | -172,819 | -189,307 | -70,641 |
| Decrease in cash and cash equivalents | -57,659 | -55,237 | -120,152 | 71,554 |
| Cash and cash equivalents at beginning of period | 74,515 | 129,752 | 178,350 | - |
| Cash and cash equivalents at end of period | 16,856 | 74,515 | 129,752 | - |
CHEMED CORP (CHE)
CHEMED CORP (CHE)